Transforming Cancer Detection: The Power of Real-World Evidence and AI in Multi-Cancer Early Detection (MCED) Studied

/in , , , , , , , , , , , , /by

Objectives:

  • Understand the Clinical Impact of MCED Testing: Gain insights into how the Falcon Registry RWE study evaluates Multi-Cancer Early Detection (MCED) testing's effectiveness across diverse patient populations and its potential to improve early cancer detection and patient outcomes.
  • Explore the Use of Real-World Data (RWD) and Advanced Prospective Data Generation: Learn about the innovative methodologies used to leverage real-world data and advanced prospective data collection technologies to support evidence generation in MCED testing.
  • Identify Strategies for Regulatory Collaboration: Gain insights into collaborative approaches between OM1 and Exact Sciences to align with regulatory expectations, aiming to advance MCED technology approvals and ensure compliance in global cancer detection initiatives and Real-world data submissions.

Access Options

External Ed SandG Featured

External Education Standards & Guidance and Templates

/in , , , , , , , , , , /by

External Ed SandG Featured

Objectives:

This S&G is intended to provide a common understanding of the framework in which External Education, led by Medical Affairs, ultimately benefits patients. The intent is to provide guidance and recommendations to Medical Affairs professionals and offer practical tools for planning, executing, and evaluating external education activities and funding determinations.

This Standard and Guidance is intended to inform learners about the Evidence Generation function, strategic direction, and operations across multiple geographies.

Access Options

Keeping it Real: Patient Engagement in Evidence Generation

/in , , , , , , , , , /by

Objectives:

Regulatory bodies such as the Food and Drug Administration (FDA) and European Medicines Agency (EMA) are increasingly recognising the value of supplementing clinical trial data with real-world evidence to improve understanding of drug performance in the healthcare setting.

Consequently, Pharma companies are increasingly including real-world studies in their evidence to:

• Understand the opportunities and best practices for involving patient partners in the generation of real-world evidence

• Explore, using case studies, the value of patient engagement in the design, delivery, analysis and communication of real-world studies

• Highlight the importance of Medical Affairs and Health Economics and Outcomes Research (HEOR) professionals in partnering with colleagues from different functions in Pharma to ensure patients are effectively engaged throughout the product lifecycle

• Discuss barriers and propose solutions to optimal patient engagement in real-world studies

Access Options

Putting the AI into Innovative Medical Affairs Teams

/in , , , , , , , , , , , /by

Objectives:

This webinar, hosted by the MAPS APAC Chapter, aims to provide a comprehensive and practical overview of how Artificial Intelligence (AI) can be integrated into various functions of Medical Affairs. Attendees will gain insights into the application of AI in medical strategy, note-taking during advisory boards, setting agendas, and enhancing scientific communication. By the end of the session, participants will have a clear understanding of the tools and techniques available, and how to implement them effectively to improve efficiency and outcomes in their roles.

Objectives:

  • Understand AI Fundamentals: Gain a basic understanding of AI and its relevance to Medical Affairs.
  • Medical Strategy Enhancement: Learn how AI can assist in developing and executing medical strategies.
  • Efficient Note-Taking and Agenda Setting: Explore AI tools for accurate note-taking and effective agenda setting during advisory boards.
  • Scientific Communication: Understand how AI can streamline and improve scientific communications.
  • Practical Implementation: Receive practical tips and best practices for integrating AI into daily Medical Affairs operations.

Access Options

Measuring the Impact of Medical Affairs: A data-driven modular approach

/in , , , , , , , , , , , /by

Objectives:

In this webinar, we will share new data showing that while medical affairs is increasing in importance, it is still struggling to reach a consensus around medical impact metrics. However, measuring medical impact is no longer a choice; it’s a necessity for medical to communicate its value as a business function and better demonstrate its contributions to successful patient outcomes.

Access Options

2024 Benchmark Report: Digital, Advanced Analytics & Artificial Intelligence in Medical Affairs

/in , , , , , , , , , , , , , , , /by

The Medical Affairs Professional Society (MAPS) is pleased to share our 2024 Digital, Advanced Analytics and Artificial Intelligence (AI) in Medical Affairs report. This report is based on findings from 32 leading organizations representing the Pharmaceutical, Biotech, and Medical and Diagnostic Device sectors, and reflects broad leadership thinking about the current and future states of Medical Affairs (MA) AI capability and challenges.

Survey design and analysis: Boston Consulting Group led the preparation, execution and analyses of the GenAI survey and moderated the Ambassador GenAI and Advanced Analytics workshop during the MAPS conference on March 24th, 2024.

Survey respondents: 34 representatives from 32 companies responded to our survey.

Participating companies: Thank you to participants from 3M, Abbott, AbbVie, Amgen, Astellas, AstraZeneca, Baxter, Bayer, bioMérieux, BioNTech, BMS, Eisai, Lilly, Gilead, Ipsen, Jazz Pharmaceuticals, Kyowa Kirin, Lundbeck, Mallinckrodt, Merck & Co, Mundipharma, Novartis, Otsuka, Regeneron, Sanofi, Sumitomo Pharma, Takeda, Teva, UCB, Varian, Vertex, and Viatris for your valuable feedback and insights.

The opinions expressed here are those of members of the MAPS Ambassador Alliance and do not necessarily represent the perspectives of their respective companies.

 

Access Options

Leveraging diverse data sources for more impactful insights analysis

/in , , , , , , , , , , , /by

Objectives:

Determining the most effective medical or commercial strategy requires measuring what’s happening in the market via a strong insights management process. Powering your insights process with different data sources (such as social media and other online conversations, medical information, congresses, advisory boards, and field observations) is critical for a full 360-degree view of the market.

In this discussion, you’ll learn:

  1. Strengths and weaknesses of different insight data sources from a business perspective
  2. How technologies like AI-supported analysis and reporting help you integrate data sources to deeply understand disease communities
  3. Real-world results pharma leaders are achieving by integrating data sources and applying AI-supported insights management processes

Access Options

Three “Generations” of Insights Implementation

/in , , , , , , , , , , , , , , , /by

From the Spreadsheet Age to the Age of Generative AI: Where is your organization on the continuum of Insights Management? (And why no one “age” fits the needs of all teams.)

Read more

Applying Data Visualization, Storytelling, and Interactivity in Medical Affairs: What Journalism Can Teach Us

/in , , , , , , , , , , /by

Objectives:

The objective is to illustrate how the strategic incorporation of interactive tools, visualization, and personalization of content can elevate the communication of medical and scientific information making it more accessible, engaging, and meaningful for diverse audiences. By embracing the innovative techniques from journalism, Medical Affairs professionals can build stronger communications with their audience, allowing for audiences to determine what they choose to view, in what order, and to the level of complexity they prefer. The presentation aims to be a facilitator for innovation, inspiring Medical Affairs professionals to adopt and adapt journalistic interactivity and visualization to their communication strategies.

Access Options

Driving Excellence: Measuring and Enhancing the Performance and Impact of Medical Affairs

Driving Excellence: Measuring and Enhancing the Performance and Impact of Medical Affairs

/in , , , , , , , , , , , , /by

Driving Excellence: Measuring and Enhancing the Performance and Impact of Medical Affairs

Objectives:

This session will delve into maximizing Medical Affairs’ performance and strategic impact through effective metrics and innovative approaches. Learn from industry experts about the strategic goals of Medical Affairs and its unique impact generation in a cross-functional environment. Discover essential metrics for assessing performance and best practices for implementation. Explore cutting-edge data generation methods and technological advancements to enhance data quality and impact measurement.

Key topics to be addressed include:

  1. What is the strategic goal of Medical Affairs and how does it generate impact?

  2. What are the key metrics to measure Medical Affairs’ performance and impact?

  3. How can innovative data approaches enhance measuring Medical Affairs’ impact?

Access Options

Connect with Us

602 Park Point Drive, Suite 225, Golden, CO 80401 – +1 303.495.2073

© 2025 Medical Affairs Professional Society (MAPS). All Rights Reserved Worldwide.

Subscribe to MAPS event and resource updates
MAPS Program Support Services
Policies and Positions